CO5130023A1 - Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico - Google Patents

Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico

Info

Publication number
CO5130023A1
CO5130023A1 CO99058265A CO99058265A CO5130023A1 CO 5130023 A1 CO5130023 A1 CO 5130023A1 CO 99058265 A CO99058265 A CO 99058265A CO 99058265 A CO99058265 A CO 99058265A CO 5130023 A1 CO5130023 A1 CO 5130023A1
Authority
CO
Colombia
Prior art keywords
active agent
growth inhibitor
administration
hybroscopic
dry powder
Prior art date
Application number
CO99058265A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Clark
Chang Kuo Mei
Lalor Cecily
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of CO5130023A1 publication Critical patent/CO5130023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CO99058265A 1998-09-14 1999-09-14 Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico CO5130023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
CO5130023A1 true CO5130023A1 (es) 2002-02-27

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99058265A CO5130023A1 (es) 1998-09-14 1999-09-14 Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico

Country Status (44)

Country Link
EP (1) EP1117442A1 (fr)
JP (1) JP2002524535A (fr)
KR (1) KR20010075063A (fr)
CN (1) CN1317977A (fr)
AP (1) AP1374A (fr)
AR (1) AR022090A1 (fr)
AU (1) AU753014B2 (fr)
BG (1) BG105430A (fr)
BR (1) BR9913722A (fr)
CA (1) CA2343920A1 (fr)
CO (1) CO5130023A1 (fr)
CZ (1) CZ2001829A3 (fr)
DZ (1) DZ2892A1 (fr)
EA (1) EA003476B1 (fr)
EE (1) EE200100151A (fr)
GE (1) GEP20043257B (fr)
GT (1) GT199900156A (fr)
HK (1) HK1042231A1 (fr)
HN (1) HN1999000159A (fr)
HR (1) HRP20010189A2 (fr)
HU (1) HUP0103837A3 (fr)
ID (1) ID28845A (fr)
IL (2) IL141562A0 (fr)
IS (1) IS5878A (fr)
LT (1) LT4897B (fr)
LV (1) LV12658B (fr)
MA (1) MA25590A1 (fr)
MY (1) MY129282A (fr)
NO (1) NO20011251L (fr)
NZ (1) NZ510168A (fr)
OA (1) OA11781A (fr)
PA (1) PA8481901A1 (fr)
PE (1) PE20001061A1 (fr)
PL (1) PL195574B1 (fr)
SA (1) SA99200718B1 (fr)
SK (1) SK3442001A3 (fr)
TN (1) TNSN99173A1 (fr)
TR (1) TR200101182T2 (fr)
TW (1) TWI226248B (fr)
UA (1) UA76085C2 (fr)
UY (1) UY25711A1 (fr)
WO (1) WO2000015262A1 (fr)
YU (1) YU24201A (fr)
ZA (1) ZA200101995B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
EP1392262A1 (fr) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
PL373780A1 (en) 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
JP2006513139A (ja) * 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
WO2004060352A1 (fr) * 2002-12-19 2004-07-22 Pharmacia Corporation Intermediaire pour formulation a caractere non-hygroscopique acceptable comprenant un bouchon hydroscopique
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
LT2708225T (lt) 2004-04-23 2019-04-10 Cydex Pharmaceuticals, Inc. Dpi kompozicija, turinti sulfoalkilo eterio ciklodekstrino
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
KR20070110418A (ko) * 2005-03-09 2007-11-16 오노 야꾸힝 고교 가부시키가이샤 입자 및 그 입자를 함유하는 제제
ES2526903T3 (es) 2005-10-26 2015-01-16 Cydex Pharmaceuticals, Inc. Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20100269819A1 (en) * 2006-08-14 2010-10-28 Sievers Robert E Human Powered Dry Powder Inhaler and Dry Powder Inhaler Compositions
CN101541311B (zh) * 2006-10-25 2013-01-23 大日本住友制药株式会社 不易结块的颗粒制剂
EP1925295A1 (fr) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Formule de poudre stable contenant un nouveau anticholinergique
JP2010524855A (ja) 2007-04-13 2010-07-22 ディフュージョン・ファーマシューティカルズ・エルエルシー 末梢血管疾患の前処置としての、及びその処置における双極性トランスカロテノイドの使用
BRPI0818119A2 (pt) 2007-10-31 2015-08-04 Diffusion Pharmaceuticals Llc Uma nova classe de produtos terapêuticos que melhoram difusão de molécula pequena
ES2661215T3 (es) * 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
EP2445339B1 (fr) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Composé améliorant la diffusion et son utilisation avec un thrombolytique
CN105287473A (zh) 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
US9682096B2 (en) 2012-05-02 2017-06-20 Janssen R & D Ireland Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
MX2017005692A (es) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
WO1993025198A1 (fr) * 1992-06-12 1993-12-23 Teijin Limited Poudre ultra-fine pour inhalation et production de cette poudre
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0954282B1 (fr) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
MY129282A (en) 2007-03-30
PA8481901A1 (es) 2002-04-25
AP1374A (en) 2005-02-28
OA11781A (en) 2005-07-26
IS5878A (is) 2001-03-05
BG105430A (en) 2001-12-29
CA2343920A1 (fr) 2000-03-23
NZ510168A (en) 2003-09-26
PE20001061A1 (es) 2000-10-08
HUP0103837A2 (hu) 2002-05-29
EP1117442A1 (fr) 2001-07-25
JP2002524535A (ja) 2002-08-06
GT199900156A (es) 2001-03-07
TWI226248B (en) 2005-01-11
PL195574B1 (pl) 2007-10-31
LV12658B (lv) 2001-09-20
IL141562A0 (en) 2002-03-10
AU6039799A (en) 2000-04-03
ZA200101995B (en) 2002-03-11
ID28845A (id) 2001-07-05
TR200101182T2 (tr) 2001-09-21
GEP20043257B (en) 2004-06-25
TNSN99173A1 (fr) 2005-11-10
AU753014B2 (en) 2002-10-03
SK3442001A3 (en) 2001-11-06
CZ2001829A3 (cs) 2001-09-12
IL141562A (en) 2007-07-24
EA200100300A1 (ru) 2001-10-22
KR20010075063A (ko) 2001-08-09
EA003476B1 (ru) 2003-06-26
LT2001021A (en) 2001-11-26
LV12658A (lv) 2001-05-20
BR9913722A (pt) 2001-05-29
HRP20010189A2 (en) 2005-04-30
DZ2892A1 (fr) 2003-12-15
EE200100151A (et) 2002-06-17
MA25590A1 (fr) 2002-12-31
UY25711A1 (es) 1999-11-17
NO20011251D0 (no) 2001-03-13
NO20011251L (no) 2001-04-17
HK1042231A1 (zh) 2002-08-09
AR022090A1 (es) 2002-09-04
SA99200718B1 (ar) 2006-11-04
YU24201A (sh) 2003-08-29
HUP0103837A3 (en) 2002-11-28
UA76085C2 (en) 2006-07-17
AP2001002093A0 (en) 2001-03-31
HN1999000159A (es) 1999-11-11
LT4897B (lt) 2002-02-25
WO2000015262A1 (fr) 2000-03-23
PL346768A1 (en) 2002-02-25
CN1317977A (zh) 2001-10-17

Similar Documents

Publication Publication Date Title
CO5130023A1 (es) Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico
CY1110376T1 (el) Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος
AR020760A1 (es) DISPOSITIVO PARA CONTROLAR LA ADMINISTRACIoN DE UN AGENTE ACTIVO EN AEROSOL EN LOS PULMONES DE UN PACIENTE HUMANO
AR059324A2 (es) Una forma solida de dosificacion oral
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
ES2159591T3 (es) Composicion de liberacion controlada.
AR015598A1 (es) FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
PE20050464A1 (es) Formulacion farmaceutica de la sal sodica del telmisartan
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
NO994431L (no) Ny formulering
CN111214689A (zh) 一种高效预防新型冠状病毒肺炎和流感的香囊
EA200200151A1 (ru) Сухая порошкообразная композиция
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
ES2176495T3 (es) Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida.
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
ECSP993140A (es) Administracion de agente activo en polvo seco
JPS5441320A (en) Slow release preparation and its manufacturing